Alnylam Pharmaceuticals

Yahoo Finance • 3 days ago

Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continue... Full story

Yahoo Finance • 10 days ago

Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth

Company Logo Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are re... Full story

Yahoo Finance • 10 days ago

Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation

Company Logo The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqv... Full story

Yahoo Finance • 15 days ago

Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabiliz... Full story

Yahoo Finance • 29 days ago

Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.

Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments... Full story

Yahoo Finance • 29 days ago

Alnylam Pharmaceuticals beats top-line and bottom-line estimates; updates FY outlook

* Alnylam Pharmaceuticals press release [https://seekingalpha.com/pr/20286227-alnylam-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-recent] (ALNY [https://seekingalpha.com/symbol/ALNY]): Q3 Non-GAAP EPS of $... Full story

Yahoo Finance • 30 days ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Altria Group (MO [https://seekingalpha.com/symbol/MO]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Enterprise Products Partners L.P. (EPD [https://seekin... Full story

Yahoo Finance • 30 days ago

Alnylam Pharmaceuticals Q3 2025 Earnings Preview

* Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) is scheduled to announce Q3 earnings results on Thursday, October 30th, before market open. * The consensus EPS Estimate is $1.75 [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • last month

Alnylam price target raised to $535 from $459 at Truist

Truist raised the firm’s price target on Alnylam (ALNY) to $535 from $459 and keeps a Buy rating on the shares ahead of its Q3 results. The firm has increased its Q3 Amvuttra sales estimate to $690M and also revised its forward estimates h... Full story

Yahoo Finance • last month

Alnylam Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Alnylam Pharmaceuticals Inc (Symbol: ALNY) have crossed above the average analyst 12-month target price of $218.18, changing hands for $222.90/share. When a stock reaches the target an analyst has set, the ana... Full story

Yahoo Finance • last month

Dow Jones Tech Titan Apple Eyes Latest Buy Point Amid Stock Market Volatility

Dow Jones tech titan Apple stock, along with Hims & Hers Health and Zscaler, are in or near buy zones amid the stock market volatility. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

SA Asks: What's the most attractive biotech stock right now?

[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader [https://seekingalpha.com/autho... Full story

Yahoo Finance • 2 months ago

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 48%?

Key Insights The projected fair value for Alnylam Pharmaceuticals is US$882 based on 2 Stage Free Cash Flow to Equity Alnylam Pharmaceuticals' US$457 share price signals that it might be 48% undervalued Analyst price target for ALNY is US... Full story

Yahoo Finance • 2 months ago

Dow Jones Futures: Bullish Market Pause; Palantir, Netflix, Oracle Right At Buy Points

The stock market rally paused at record highs. Palantir, Netflix and Oracle lead several stocks right around buy points. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Alnylam yanks Amvuttra TV ad following FDA letter - report

[View of Alnylam Pharmaceuticals company office facade with logo signs, Biotechnology industry] Veronique D/iStock Editorial via Getty Images Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) has pulled a televi... Full story

Yahoo Finance • 2 months ago

Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Wealth Enhancement Advisory Services LLC trimmed its position in Alnylam Pharmaceuticals, In... Full story

Yahoo Finance • 2 months ago

3 Stocks That May Be Trading Below Estimated Fair Value

As the U.S. stock market navigates through a government shutdown and unexpected private-sector job losses, major indices like the Nasdaq and S&P 500 continue to show resilience, with recent gains bringing them near record highs. In this fl... Full story

Yahoo Finance • 2 months ago

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

- Global Cardiovascular Outcomes Trial will Enroll ~11,000 Patients Across 35 Countries to Evaluate Zilebesiran as a Novel Biannual Treatment - - Trial to Assess Zilebesiran in Patients with Uncontrolled Hypertension with Either Establish... Full story

Yahoo Finance • 2 months ago

Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interferenc... Full story

Yahoo Finance • 2 months ago

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

− Treatment with Vutrisiran Led to 37- 49% Lower Rates of Gastrointestinal Events, a Multisystem Manifestation of ATTR-CM, Across Multiple Treatment Groups, Compared to Placebo – − Additional Analyses Reinforce Vutrisiran’s Safety and Eff... Full story